Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients
Launched by GILEAD SCIENCES · Aug 30, 2001
Trial Information
Current as of March 16, 2025
Completed
Keywords
ClinConnect Summary
Patients are randomized 2:1 to add tenofovir DF once daily or placebo to their existing antiretroviral regimen in a blinded manner. Patients are stratified according to HIV-1 RNA level, CD4 cell count, and number of antiretroviral drugs taken prior to study entry. Patients and physicians are strongly discouraged from making changes in their antiviral therapies for at least 24 weeks post-randomization. After Week 24, changes in background antiretroviral therapy are permitted. At 24 weeks post-randomization, patients randomized to receive placebo are crossed over to receive open-label tenofov...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients may be eligible for this study if they:
- • Are HIV-positive.
- • Have been on stable anti-HIV therapy for at least 8 weeks with no more than 4 anti-HIV drugs at the time of study entry.
- • Have a viral load (level of HIV in the blood) between 400 and 10,000 copies/ml.
- • Have good kidney function.
- • Are 18 to 65 years old.
- • Agree to use a barrier method of birth control (such as condoms) during the study and for 30 days after.
- • Exclusion Criteria
- Patients will not be eligible for this study if they:
- • Have a new AIDS-related illness diagnosed within 30 days of study entry.
- • Have any other serious medical conditions, including kidney or bone disease, an active infection requiring antibiotics, or cancer (other than Kaposi's sarcoma or certain skin cancers).
- • Have received a vaccine within 30 days of study entry.
- • Are unable to take medications by mouth.
- • Have ever taken tenofovir or adefovir dipivoxil.
- • Have taken certain medications within 30 days of study entry, such as chemotherapy, corticosteroids, medications that affect the kidneys, treatment for Kaposi's sarcoma, or certain experimental drugs.
- • Abuse alcohol or drugs.
- • Are pregnant or breast-feeding.
About Gilead Sciences
Gilead Sciences is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to address unmet medical needs. With a strong emphasis on antiviral therapies, particularly for HIV, hepatitis B, hepatitis C, and influenza, Gilead leverages advanced research and development capabilities to drive breakthroughs in treatment and care. The company is committed to improving patient outcomes through rigorous clinical trials, fostering collaborations with healthcare professionals, and engaging in partnerships to enhance global health. Gilead's dedication to scientific excellence and patient-centric approaches positions it at the forefront of the biopharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Birmingham, Alabama, United States
Bronx, New York, United States
Rochester, New York, United States
Washington, District Of Columbia, United States
Boston, Massachusetts, United States
Los Angeles, California, United States
Providence, Rhode Island, United States
Detroit, Michigan, United States
Los Angeles, California, United States
Ponce, , Puerto Rico
Dallas, Texas, United States
San Antonio, Texas, United States
Boston, Massachusetts, United States
New York, New York, United States
Hampton, Virginia, United States
San Diego, California, United States
San Francisco, California, United States
Hershey, Pennsylvania, United States
Phoenix, Arizona, United States
Vero Beach, Florida, United States
Santurce, , Puerto Rico
Los Angeles, California, United States
Annandale, Virginia, United States
Los Angeles, California, United States
Oakland, California, United States
Columbus, Ohio, United States
Houston, Texas, United States
Denver, Colorado, United States
Albany, New York, United States
San Francisco, California, United States
Tampa, Florida, United States
Tacoma, Washington, United States
Chicago, Illinois, United States
Miami, Florida, United States
New York, New York, United States
Oklahoma City, Oklahoma, United States
Fort Lauderdale, Florida, United States
Atlanta, Georgia, United States
Brooklyn, New York, United States
San Juan, , Puerto Rico
Torrance, California, United States
New Haven, Connecticut, United States
Charlotte, North Carolina, United States
Atlanta, Georgia, United States
Houston, Texas, United States
San Francisco, California, United States
Long Beach, California, United States
Washington, District Of Columbia, United States
Long Beach, California, United States
Dallas, Texas, United States
Los Angeles, California, United States
New Haven, Connecticut, United States
Fort Pierce, Florida, United States
Lafayette, Louisiana, United States
Baltimore, Maryland, United States
St. Paul, Minnesota, United States
Albuquerque, New Mexico, United States
New York, New York, United States
Columbus, Ohio, United States
Puyallup, Washington, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials